|
|
Дата |
|---|
| 18.11.2026 |
| 17.11.2026 |
| 16.11.2026 |
| 13.11.2026 |
| 12.11.2026 |
| 11.11.2026 |
| 10.11.2026 |
| 09.11.2026 |
| 06.11.2026 |
| 05.11.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
|
|
32.29
|
32.29
|
32.29
|
32.29
|
|
|
3 229.00
|
1.00
|
|
|
|
29.97
|
29.97
|
29.97
|
29.97
|
|
|
2 997.00
|
1.00
|
|
|
|
|
|
|
32.83
|
|
|
|
|
|
|
|
|
|
|
32.83
|
|
|
|
|
|
|
|
32.30
|
32.30
|
32.30
|
32.30
|
|
|
64.60
|
1.00
|
|
|
|
|
|
|
30.12
|
|
|
|
|
|
|
|
30.12
|
30.12
|
30.12
|
30.12
|
|
|
301.20
|
1.00
|
|
|
|
|
|
|
30.00
|
|
|
|
|
|
|
|
30.00
|
30.00
|
30.00
|
30.00
|
|
|
150.00
|
1.00
|
|
|
|
28.18
|
28.18
|
28.18
|
28.18
|
|
|
5 636.00
|
2.00
|
Lycia Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases. Its immunoglobulin E (IgE) portfolio consists of LCA-0061 and LCA-0062. The LCA-0061 is an antibody-small molecule conjugate cataLYTAC degrader designed to target and degrade IgE, a known driver of multiple allergic diseases, including food allergy, allergic asthma, allergic rhinitis, chronic spontaneous urticaria and chronic rhinosinusitis with nasal polyps.
The LCA-0062 bispecific antibody cataLYTAC degrader is designed to target and degrade IgE, it is designed to degrade multiple copies of IgE per LYTAC degrader. LCA-0321 is a protein-small molecule conjugate classic LYTAC degrader which is designed to selectively degrade TRAbs, the pathogenic drivers of Graves' disease.
Показать все Скрыть